Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

$Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.$

Posted by Medivizor on May 8, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Posted by Medivizor on Nov 27, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

$How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?$

Posted by Medivizor on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients. Some background B-NHL is a type of...

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

$Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.$

Posted by Medivizor on Aug 22, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

$Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.$

Posted by Medivizor on Aug 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of tandem chimeric antigen receptor (tCAR) T-cell therapy for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that tCAR T-cell therapy resulted in long-term remission rates with manageable side effects for these patients. Some...

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by Medivizor on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Posted by Medivizor on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

$Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?$

Posted by Medivizor on Jul 31, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

$Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?$

Posted by Medivizor on Jul 31, 2021 in Non-Hodgkin lymphoma | 0 comments

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Posted by Medivizor on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Posted by Medivizor on Jul 11, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

$Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML$

Posted by Medivizor on Jun 27, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...

« Older Entries

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Categories

Recent Posts

Archives

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email